AT9283

For research use only. Not for use in humans.

目录号:S1134

AT9283 Chemical Structure

CAS No. 896466-04-9

AT9283是一种有效的JAK2/3抑制剂,无细胞试验中IC50为1.2 nM/1.1 nM;对Aurora A/B,Abl1(T315I)也有效。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2444.92 现货
RMB 818.33 现货
RMB 1380.26 现货
RMB 2232.59 现货
RMB 6298.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的AT9283发表文献22篇:

产品安全说明书

JAK抑制剂选择性比较

生物活性

产品描述 AT9283是一种有效的JAK2/3抑制剂,无细胞试验中IC50为1.2 nM/1.1 nM;对Aurora A/B,Abl1(T315I)也有效。Phase 2。
特性 AT9283是有效的pan-aurora 抑制剂。
靶点
JAK3 [1]
(Cell-free assay)
JAK2 [1]
(Cell-free assay)
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
Abl1 (T315I) [1]
(Cell-free assay)
1.1 nM 1.2 nM ~3.0 nM ~3.0 nM 4 nM
体外研究

在体外, AT9283有效抑制多种激酶,包括 Aurora A, Aurora B, JAK3, JAK2和 Abl,IC50分别为3 nM, 3 nM, 1.1 nM, 1.2 nM 和 4 nM。AT9283 作用于HCT116 细胞,通过抑制Aurora B 激酶活性,产生明显的多倍体表现型,IC50为30 nM。而且, AT9283也有效抑制HCT116形成集落。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NHniSpNEgXSxdH;4bYNqfHliYYPzZZk> MmK1NVAhfG9iMUSg[IF6ew>? MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiboXtZoVzKG:oIHPvcI9vcWW|IHHmeIVzKDFyIITvJFE1KGSjeYOgZpkh[2:ub375JIZwem2rbnegZZN{[XluIFnDOVA:OC5yMUNOwG0> NFe3dWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG0N|U3Pyd-MUmxOFM2Pjd:L3G+
HCT116 Mnf5SpVv[3Srb36gZZN{[Xl? NVvsb|YyOTBibXevb4c> NH73b2lEdWG6IHnuJGJCVEJxYzDtc5V{\SCkZXHybY5oKGi3bXHuJGhEXDFzNjDj[YxteyCjdDCxNEBu\y:tZzygdI8tKEOvYYi9NE41Pc7:TR?= NYrBRXE4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxOFM2PjdpPkG5NVQ{PTZ5PD;hQi=>
HCT116 MX;GeY5kfGmxbjDhd5NigQ>? M1LtblUhdWdxa3e= MljvR41igCCrbjDCRWxDN2NibX;1d4Uh[mWjcnnu[{BpfW2jbjDIR3QyOTZiY3XscJMh[XRiNTDt[{9s\yxiaY[sJGNu[Xh;ND65{txO NV\sd2p6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxOFM2PjdpPkG5NVQ{PTZ5PD;hQi=>
HCT116 MoXVSpVv[3Srb36gZZN{[Xl? MV[yNEBu\y:tZx?= MVzDcYF5KGmwIFLBUGIw[yCvb4Xz[UBj\WG{aX7nJIh2dWGwIFjDWFEyPiClZXzsd{BifCB{MDDt[{9s\yxiaYCsJGNu[Xh;OD60{txO MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF2M{W2O{c,OTlzNEO1Olc9N2F-
HT-29 M{LBVWFvfGm2dX3vdkBie3OjeR?= MYC3NkBpenN? NFHyXFlCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuN|g{|ryP NF2zV5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2OFA6QSd-MkO2OlQxQTl:L3G+
A549 NGPoUJJCdnSrdIXtc5Ih[XO|YYm= NFHDTmY4OiCqcoO= NVjpNpNuSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOVEz|ryP Ml7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NkSwPVkoRjJ|Nk[0NFk6RC:jPh?=
LoVo M1;0R2FvfGm2dX3vdkBie3OjeR?= NXnDem9sPzJiaILz MlHERY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwNUWz{txO MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4NEC5PUc,OjN4NkSwPVk9N2F-
K562 NWLCdnA{SW62aYT1cY9zKGG|c3H5 NXX3fmdbPzJiaILz M331fmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkdOwG0> MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NkSwPVkoRjJ|Nk[0NFk6RC:jPh?=
U937 M1T6b2FvfGm2dX3vdkBie3OjeR?= NWTwV2hrPzJiaILz NUDRS5h3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[uO:69VQ>? NEfOXZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2OFA6QSd-MkO2OlQxQTl:L3G+
BL21 (DE3) NUPvTlAyTnWwY4Tpc44h[XO|YYm= NGHzVW0{OCCvaX7z MmL3TY5pcWKrdHnvckBw\iCKaYO2MZRi\2enZDDNSWxMKGOjdHHsfZRq[yCmb33hbY4hMDFidH:gN|QxKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNidYPpcochSmOuLVfMJIF{KHO3YoP0doF1\SCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIlvKHC{ZYPlcoNmKG:oIGvnZY1u[TN{UG3BWHAh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnegcYV1cG:mLDDJR|UxRTBwNki1{txO MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MU[wO{c,Ojh|NUG2NFc9N2F-
Sf9 MUXGeY5kfGmxbjDhd5NigQ>? NIjZO5pDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlv[WxiVFXWMYNt\WG4YXLs[UBp\XijLXjpd5Rq\GmwZTD0ZYdo\WRiaIXtZY4hUkGNMjDKTFEh\G:vYXnuJEg5PDBidH:gNVE{OiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoOTDj[YxteyCkeTDJWGMh[XO|YYmsJGtlRTBwMEGx{txO M1q3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkK2OVIyLz5{OE[yOlUzOTxxYU6=
Sf9 NVvOdlZYTnWwY4Tpc44h[XO|YYm= M2PLfWJqdmSrbnegZYZncW6rdImgeI8hSy22ZYLtbY5idCC2aILvcYJqdi2lbHXheoFjdGViaHX4ZU1pcXO2aXTpcoUhfGGpZ3XkJIh2dWGwIFrBT|IhUkh{IIDz[ZVld2urbnHz[UBld22jaX6gLFU{PiC2bzC4NVIhemW|aXT1[ZMqKFd4NUnBM3c4PzeDL1[3PVRJKG23dHHueEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOtbY5n\WO2ZXSgV4Y6KGOnbHzzJIJ6KEmWQzDhd5NigSxiS3S9NU4{OjQQvF2= Mn;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4Mk[1NlEoRjJ6NkK2OVIyRC:jPh?=
Sf9 NIjzOXlHfW6ldHnvckBie3OjeR?= M3v5dVExKHWP MY[2NEBucW6| MXPEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUGWUDDmdo9uKENvdHXycYlv[WxidHjyc41jcW5vY3zlZZZi[mynIHjlfIEucGm|dHnkbY5mKHSjZ3fl[EBpfW2jbjDKRWszKEqKMjDwd4V2\G:taX7hd4Uh\G:vYXnuJEg2OzZidH:gPFEzKHKnc3nkeYV{MSCZNkW5RU9YPzd5QT;GO|k1UCCvdYThcpQh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{BifCBzMDD1UUBi\nSncjC2NEBucW6|IHL5JIhq\2hvdHjyc5VocHC3dDDmcJU> NYXaS4V1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NlY2OjFpPkK4OlI3PTJzPD;hQi=>
HCT116 MlHpSpVv[3Srb36gZZN{[Xl? Mn[zTY5pcWKrdHnvckBw\iCDdYLvdoEhSiCtaX7hd4UhcW5iaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCyb3z5dIxwcWRicHjlco91gXCnLDDJR|UxRTBwMEROwG0> MnX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7MUiwPVYoRjJ6OUG4NFk3RC:jPh?=
DAOY M4LBbZFJXFNiYYPzZZk> M4\zNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| M3XkV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 M4[wUpFJXFNiYYPzZZk> Mn3FdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NFnMSXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MoLZdWhVWyCjc4PhfS=> NIj6U25yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NHrReoNyUFSVIHHzd4F6 NInxSo9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NXTJUZd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MoPrdWhVWyCjc4PhfS=> NXHDdYtleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 Mkn5dWhVWyCjc4PhfS=> MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
U-2 OS NGfXfm1yUFSVIHHzd4F6 M{HUR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCXLUKgU3Mh[2WubIO= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 NXS4R2MzeUiWUzDhd5NigQ>? MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NYrUNVJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M2TpTpFJXFNiYYPzZZk> MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NHXBVZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 M1SwdpFJXFNiYYPzZZk> NHnF[4lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MnTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NXvZfYgyeUiWUzDhd5NigQ>? M3HRNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 M1nkO5FJXFNiYYPzZZk> NUHmSXlleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz NIfxSXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 NGnxc|ByUFSVIHHzd4F6 MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NV:1PJNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NX3iUYRZeUiWUzDhd5NigQ>? NXPo[JBTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NFnBR4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD NUD4Xpo4eUiWUzDhd5NigQ>? M2e5[pFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? M1S1[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) NEDaWndyUFSVIHHzd4F6 NFz6WYVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NHnzfWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
fibroblast cells MYnxTHRUKGG|c3H5 NV7UeVBVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IHPvcpRzd2xiSHige4lt\CC2eYDlJIZq[nKxYnzhd5Qh[2WubIO= NVXzeXJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NFW4ZnByUFSVIHHzd4F6 M4jIT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| NY\UWVBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC MUHxTHRUKGG|c3H5 M4fNV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? NFnEOmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Growth inhibition assay
Cell viability; 

PubMed: 21430070     


AT9283 reduces MM cells viability in a dose dependent manner. Cells were treated with increasing doses of AT9283 for 72 hours and cell viability was measured by MTT assay

21430070
体内研究 AT9283 按15 mg/kg和 20 mg/kg剂量作用于携带HCT116人结肠癌移植瘤的小鼠,持续16天,显著抑制肿瘤生长,抑制分别达67%和76%。此外, 与血浆(半衰期为0.5小时)相比,AT9283口服给药小鼠,也具有显著较长的半衰期。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

Aurora A和 Aurora B激酶实验:

在DELFIA格式中进行Aurora A 和 B实验。Aurora A 酶和AT9283 及 3 μM 肽底物 (生物素-CGPKGPGRRGRRRTSSFAEG)在 10 mM MOPS, pH 7, 0.1 mg/mL BSA, 0.001% Brij-35, 0.5% 甘油, 0.2 mM EDTA, 10 mM MgCl2, 0.01% β-巯基乙醇, 15 μM ATP,和2.5% DMSO混合物中温育。Aurora B 酶和AT9283,及3 μM 以上底物在25 mM Tris, pH 8.5, 5 mM MgCl2, 0.1 mg/mL BSA, 0.025% Tween-20, 1 mM DTT, 15 μM ATP, 和 2.5% DMSO的混合物中温育。Aurora A 和 Aurora B反应分别进行60分钟和45-90分钟,然后使用 EDTA进行淬火。反应混合物转移到亲和素包被的实验板上,通过时间分辨荧光技术(激发波长, 337 nm;发射波长, 620 nm),使用特定磷酸抗体和铕标记的二抗测量磷酸化的肽。
细胞实验:[1]
- 合并
  • Cell lines: HCT 116 细胞
  • Concentrations: 1 nM 到10 μM
  • Incubation Time: 72 小时
  • Method: HCT 116细胞培养在DMEM +10% FBS + GLUTAMAX I 中。细胞接种在黑色96孔平底组织培养板中,孔中含200 μL 培养基,在37oC 下温育约16小时,在湿润且含5% CO2 的环境下温育约16小时。使用9种不同浓度AT9283 (为 1 nM到 10 μM, 对照组为DMSO) 处理细胞,然后再温育72小时。 标记对细胞多倍体形态学的观察。记录产生明显多倍体所需AT9283的浓度。细胞按75−100个细胞/mL接种在有关培养基中,然后转移到6-或24-孔组织培养板上,然后覆盖培养16小时。AT9283(11 种浓度,0.1 nM 到 10 μM) 或对照组(DMSO) 加到复制孔中,DMSO终浓度为0.1%。随后加入AT9283,集落生长10和14天,计算最佳离散菌落数。集落在2 mL Carnoys 固定液(25% 乙酸,75% MeOH)中固定,然后在2 mL 0.4% w/v 结晶紫中染色。计算每孔中集落数。使用Prism Graphpad 软件绘制IC50曲线,通过S形剂量反应曲线计算IC50值。
    (Only for Reference)
动物实验: [1]
- 合并
  • Animal Models: 后腿侧皮下注射HCT116细胞的雄性BALB/c小鼠
  • Dosages: 15 mg/kg 和 20 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 76 mg/mL (199.25 mM)
Ethanol 38 mg/mL (99.62 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 381.43
化学式

C19H23N7O2

CAS号 896466-04-9
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01145989 Completed Drug: AT9283 Multiple Myeloma NCIC Clinical Trials Group|Astex Pharmaceuticals Inc.|Canadian Cancer Trials Group June 15 2010 Phase 2
NCT00443976 Completed Drug: Aurora kinase inhibitor AT9283 Non-Hodgkins Lymphoma|Unspecified Adult Solid Tumor Protocol Specific NCIC Clinical Trials Group|Astex Pharmaceuticals Inc.|Canadian Cancer Trials Group January 4 2007 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

相关JAK产品

Tags: 购买AT9283 | AT9283供应商 | 采购AT9283 | AT9283价格 | AT9283生产 | 订购AT9283 | AT9283代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID